Search

The article discusses the genetic factors contributing to hypertrophic cardiomyopathy (HCM) in the elderly population, a condition primarily caused by gene variants affecting heart muscle structure and function. Researchers collected and sequenced genetic data from Indian Wellderly individuals to identify nebulin-related anchoring protein (NRAP) as a gene associated with elderly HCM. Functional analysis revealed reduced interactions of the NRAP variant with key proteins, suggesting a loss of function. The study highlights the importance of ethnic-specific genomic data in identifying genes linked to diseases and emphasizes the value of the Indian Wellderly database for future research. [Extracted from the article]

A study conducted at University Hospital Munster in Germany reported on a rare case of hypertrophic cardiomyopathy (HCM) in a 60-year-old male patient. The patient was diagnosed with transthyretin amyloidosis and a chromosomal duplication affecting cardiac myosin genes, leading to an unusual presentation of HCM. This case highlights the complexity of genetic and non-genetic factors contributing to HCM and underscores the need for further research in understanding these rare disease entities. [Extracted from the article]

A patent has been issued for an RF ablation catheter designed for septal reduction therapy with a cooling effect by Tau Medical Inc. The catheter is intended for treating conditions such as hypertrophic cardiomyopathy and ventricular tachycardia by applying RF energy to the interventricular septum. The design includes features to prevent tissue carbonization and facilitate RF transmission, widening the range of cauterization. [Extracted from the article]

Researchers at the University of British Columbia conducted a study, known as the REHAB-HCM study, to explore the impact of cardiac rehabilitation (CR) on patients with Hypertrophic Cardiomyopathy (HCM) and metabolic syndrome. The study aimed to assess the feasibility, safety, and efficacy of a structured 3-month CR program for this patient population. The researchers concluded that exercise and CR could be beneficial for HCM patients with metabolic syndrome without significant exercise-related harms. The study was supported by various organizations including St Paul's Foundation and the Canadian Institutes of Health Research. [Extracted from the article]

Researchers from Coimbra Hospital and University Center have conducted a study on disease progression in Hypertrophic Cardiomyopathy (HCM). The study focuses on the use of PET-CT imaging to assess risk stratification and prognosis in HCM patients. The research highlights the potential of PET imaging in evaluating factors such as myocardial blood flow, metabolism, and fibroblast activation to enhance predictive accuracy and monitor therapeutic outcomes in HCM patients. Further research is needed to fully understand the role of PET in risk assessment for HCM. [Extracted from the article]

The article discusses a new artificial intelligence-based approach called Segmentation based Myocardial Advanced Refinement Tracking (SMART) for assessing left ventricular mass (LVM) and global longitudinal strain (LVGLS) in patients with hypertrophic cardiomyopathy (HCM). The study included 111 HCM patients and found that SMART provided a more accurate assessment of LVM compared to conventional methods, with predictive value for myocardial fibrosis and adverse outcomes. The SMART technique shows promise in improving the management of HCM by offering a comparable evaluation of LVGLS and more accurate assessment of LVM. [Extracted from the article]

A recent study conducted at New York University (NYU) Langone Health focused on the use of disopyramide in treating heart failure symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM). The research involved 92 patients with symptomatic obstructive HCM who were maintained on disopyramide for over 5 years, showing that the medication was effective in reducing outflow obstruction and relieving heart failure symptoms in a subgroup of patients. The study concluded that disopyramide is safe and effective for long-term treatment of symptomatic obstructive HCM. [Extracted from the article]

A recent report from Yale University explores the distinct mechanisms that drive divergent clinical phenotypes in hypertrophic and dilated cardiomyopathy-associated Tpm1 variants. The study focuses on mutations within the TPM1 gene and their impact on muscle contractility, gene expression, and potential treatments. By conducting experiments with stem cell-derived cardiomyocytes and computational simulations, researchers were able to provide plausible explanations for the different effects of specific mutations on heart function. This research sheds light on the complex interplay between genetic mutations and cardiac health, offering insights that could inform future treatments for heart disorders. [Extracted from the article]

Researchers from Xiang-ya School of Medicine in Haikou, People's Republic of China, have published a report on the twin phenomena of Hypertrophic Cardiomyopathy (HCM), a genetic cardiovascular disease characterized by thickening of the left ventricular wall. The study explores the genetic and epigenetic factors influencing HCM in twins, emphasizing the importance of genetic screening for early diagnosis and personalized treatment. This research aims to enhance understanding of the complex genetic background of HCM, potentially leading to more tailored management strategies. [Extracted from the article]

Researchers from the Russian Academy of Sciences conducted a study on the effects of mutations in cardiac myosin binding protein-C (cMyBP-C) on muscle contraction. The mutations D75N and P161S were found to impact force generation and calcium sensitivity in muscle fibers, potentially leading to cardiac diastolic dysfunction and myocardial hypertrophy. This research was supported by the Russian Science Foundation and was published in the International Journal of Molecular Sciences. [Extracted from the article]

A patent has been issued for materials and methods to treat Friedreich's Ataxia, a rare genetic disorder that causes progressive neurological and cardiac dysfunction. The patent describes a new fusion polypeptide that aims to overcome limitations of existing treatments by providing higher solubility and allowing for higher doses to be administered. This development addresses the urgent need for new therapies to treat Friedreich's Ataxia, which currently has no cure. [Extracted from the article]

Researchers from the Vascular and Thoracic Institute have conducted a study on hypertrophic cardiomyopathy, specifically focusing on the echocardiographic changes following surgical myectomy in severely symptomatic obstructive hypertrophic cardiomyopathy. The study involved 173 adults who underwent myectomy between March 2017 and June 2020, with improvements observed in left atrial volume index, E/e', and peak left ventricular outflow tract gradient. While various echocardiography parameters improved at the one-year mark, the study found that left ventricular global longitudinal strain remained unchanged. The findings suggest that myectomy can enhance certain echocardiographic parameters in patients with obstructive hypertrophic cardiomyopathy. [Extracted from the article]

A researcher at Florida State University has conducted a study on the role of mechanosignaling in controlling myocardial mass, which is crucial for cardiovascular health. The study highlights the complex relationship between mechanosignaling and myocardial mass, influenced by factors like hemodynamic and microgravity. Dysregulation of these processes can lead to pathological cardiac remodeling, emphasizing the importance of protein quality control mechanisms in extreme physiological conditions. The research provides insight into how mechanical signals are converted into chemical signals to regulate myocardial mass in both healthy and diseased conditions. [Extracted from the article]

A recent study from the Division of Cardiology focused on the effects of genetic mutations on left ventricular myocardial mechanics and fibrosis patterns in hypertrophic cardiomyopathy (HCM). The research found that myocyte disarray and fibrosis are key pathologies in HCM caused by genetic mutations. Patients with sarcomere-associated mutations exhibited specific cardiac abnormalities, such as lower circumferential strain and higher prevalence of midepicardial fibrosis. The study concluded that while certain genetic mutations were associated with specific cardiac abnormalities, longitudinal fiber function was correlated with the extent of hypertrophy and fibrosis in HCM. [Extracted from the article]

A recent study from the University of Virginia explores the use of cardiac myosin inhibitors (CMIs) as a potential pharmacological treatment for Hypertrophic Cardiomyopathy (HCM), an inherited heart condition characterized by left ventricular hypertrophy. The research suggests that CMIs could be a safe and effective second-line option for managing HCM, with ongoing studies investigating their role in standard treatment. This peer-reviewed study highlights the potential of CMIs in the future management of HCM. [Extracted from the article]

Research from Shanghai focused on the differential diagnostic value of left ventricular segmental myocardial strain in distinguishing between cardiac amyloidosis (CA) and non-obstructive hypertrophic cardiomyopathy (HCM). The study involved 20 patients with immunoglobulin light chain cardiac amyloidosis (AL-CA) and 20 patients with non-obstructive HCM. Results showed that certain strain parameters were lower in the CA group compared to the HCM group, with BASAL-ANT/LAT identified as an independent factor in distinguishing between the two conditions. The research concluded that left ventricular segmental myocardial strains are effective in differentiating between AL-CA and HCM, with BASAL-ANT/LAT having the highest application value. [Extracted from the article]

A recent study from the Russian Medical Academy of Postgraduate Education delves into the prevalence, etiology, and genetic mutations associated with hypertrophic cardiomyopathy. The research explores various aspects of the condition, including pathophysiology, diagnostic imaging techniques, treatment options, and risk factors for sudden death. The findings emphasize the importance of accurate diagnosis and personalized treatment strategies for individuals with hypertrophic cardiomyopathy. [Extracted from the article]

Researchers at Columbia University have developed a machine learning model to predict new-onset atrial fibrillation (AF) in patients with hypertrophic cardiomyopathy (HCM). The model outperformed the conventional HCM-AF score in terms of sensitivity and specificity, with key clinical variables including left atrial volume, left ventricular outflow tract gradient, and late gadolinium enhancement on cardiac magnetic resonance imaging. This study provides a more accurate tool for predicting AF in HCM patients, potentially improving risk assessment and prevention strategies. [Extracted from the article]

A recent study conducted at Duke University introduced a new tool, the Cardiovascular Disease Pathogenicity Predictor (Cvd-pp), designed to help differentiate between pathogenic and benign variants in cardiovascular disease genes. The model demonstrated high accuracy in prioritizing variants with changed clinical significance and in identifying individuals with dilated cardiomyopathy. This research could potentially aid in genetic diagnosis and large-scale genomic sequencing studies related to cardiovascular diseases. For more information, readers can refer to the original article published in Circulation: Genomic and Precision Medicine. [Extracted from the article]

Researchers at Osaka University have identified four patients with cardiomyopathy who possess a heterozygous DSG2 p.Arg119Ter variant, which is more prevalent in this population than in the general Japanese population. These patients exhibited various forms of cardiomyopathy and reduced left ventricular function, with additional possible causative genetic variants identified. The study suggests that desmosome impairment may contribute to contractile dysfunction and disease progression in these patients. For more information, readers can refer to the article "Four cardiomyopathy patients with a heterozygous DSG2 p.Arg119Ter variant" published in Human Genome Variation. [Extracted from the article]

Researchers at Brigham and Women's Hospital in Boston, Massachusetts, have found that transatrial transcatheter mitral valve replacement can simplify mitral valve procedures for high-risk patients with mitral annular calcification. The study analyzed trends in the use of this technique and its outcomes, showing a decrease in mortality and major adverse cardiac events in recent years. The research suggests that transatrial transcatheter mitral valve replacement may play a significant role in treating patients with mitral annular calcification. [Extracted from the article]

Researchers at the University of Alabama Birmingham conducted a study to evaluate sex-associated differences in outcomes for patients with hypertrophic cardiomyopathy undergoing septal myectomy and alcohol septal ablation. The study found that the risk of short- and long-term mortality was similar for male and female patients undergoing these procedures. The research concluded that sex-based differences in clinical presentation should not deter consideration of septal reduction therapies for hypertrophic cardiomyopathy. This study was supported by the NIH National Heart Lung & Blood Institute and has been peer-reviewed. [Extracted from the article]

A recent study conducted at the Fourth Affiliated Hospital explored the relationship between disulfidptosis and hypertrophic cardiomyopathy, identifying potential biomarkers and therapeutic targets for the condition. The study highlighted the predictive model containing disulfidptosis-associated genes (DRGs) and the use of resveratrol as a therapeutic drug targeting core genes. This research provides new insights into the pathogenesis of hypertrophic cardiomyopathy and offers avenues for further exploration in this field. [Extracted from the article]

Researchers from Worcester Polytechnic Institute have developed a novel framework called HCM-Echo-VAR-Ensemble to detect Hypertrophic Cardiomyopathy (HCM) in echocardiogram videos with high accuracy. The framework combines deep VAR architectures models (SlowFast and I3D) and achieved a state-of-the-art accuracy of 95.28%. This approach shows promise in improving the sensitivity and accuracy of HCM detection in clinical settings, potentially enhancing diagnostic consistency and reliability, even in low-resource environments. The research was published in the IEEE Open Journal of Engineering in Medicine and Biology. [Extracted from the article]

Researchers at University Hospitals Coventry and Warwickshire NHS Trust conducted a study to estimate the resource use of patients with obstructive hypertrophic cardiomyopathy (HCM) in the English and Northern Irish healthcare systems. The study involved cardiologists treating patients with HCM, with findings showing an increase in primary and secondary care consultations as New York Heart Association (NYHA) class increased. The research highlighted the clinical and economic burden associated with treating obstructive HCM, emphasizing the need for intensive disease management, hospitalizations, and potential septal reduction therapies. [Extracted from the article]

Researchers at Regina Montis Regalis Hospital published a case study on a 49-year-old patient with atypical chest pain and hypertrophic cardiomyopathy, ultimately diagnosed with Anderson-Fabry disease. The study utilized cardiac magnetic resonance imaging and native myocardial T1 mapping to identify characteristic features of the disease, such as reduced native T1 values. The findings suggest that these imaging techniques can serve as a valuable diagnostic tool, potentially streamlining assessments and reducing unnecessary costs and radiation exposure. For more information, readers can access the full article in the Monaldi Archives for Chest Disease. [Extracted from the article]

The University of California researchers published a case report on verapamil toxicity leading to haemodynamic compromise in obstructive hypertrophic cardiomyopathy. Verapamil, commonly used to treat symptomatic patients, was found to have adverse effects in this case, resulting in cardiogenic shock. The patient experienced rapid symptom relief after discontinuing the medication and receiving conservative management. The report highlights the potential adverse effects of verapamil use in patients with obstructive HCM. [Extracted from the article]

A recent study conducted by researchers from the University of Leeds focused on hypertrophic cardiomyopathy, comparing 2D and 3D feature tracking cardiac magnetic resonance (FT-CMR) in patients with the condition. The study found that 3D FT-CMR is feasible in patients with hypertrophic cardiomyopathy and offers advantages such as not requiring additional scanning time. The research highlighted differences in myocardial strain between 2D and 3D FT-CMR, with 3D values consistently lower, and noted variations in strain levels between different phenotypes of hypertrophic cardiomyopathy. [Extracted from the article]

The article discusses the challenges faced by individuals with hypertrophic cardiomyopathy in accessing treatment due to barriers such as health insurance obstacles. It emphasizes the importance of timely and tailored treatment to improve health outcomes for patients with this condition. The Alliance for Patient Access released a policy paper highlighting the disease, its treatment options, and the need for policy changes to facilitate better care for individuals with hypertrophic cardiomyopathy. [Extracted from the article]

A recent study conducted at Amsterdam University Medical Center explored the feasibility of using 4D-flow cardiac magnetic resonance imaging (4D-flow CMR) to assess postoperative hemodynamic differences in patients with hypertrophic cardiomyopathy (HCM) who underwent septal myectomy with and without anterior mitral valve leaflet extension (AMVLE). The study found that patients who underwent myectomy with concomitant AMVLE exhibited lower aortic wall shear stress, lower left ventricular outflow tract (LVOT) peak velocity, higher kinetic energy in the LVOT, and lower kinetic energy in the ascending aorta compared to patients who underwent isolated myectomy. The research suggests that incorporating AMVLE in surgical approaches for HCM patients may lead to better hemodynamic outcomes. [Extracted from the article]

Recent research conducted at the National Medical Research Center of Cardiology in Moscow, Russia, focuses on hypertrophic cardiomyopathy (HCM), a genetic cardiac disorder associated with various risks. The study highlights the potential of circulating microRNAs as biomarkers for HCM, offering insights into diagnosis, disease monitoring, and therapeutic strategies. The research emphasizes the use of advanced cardiac magnetic resonance techniques to identify specific myocardial features associated with HCM. This study provides valuable information for individuals interested in cardiovascular diseases and conditions, particularly those related to HCM. [Extracted from the article]

A study conducted by the Ministry of Health in Vietnam identified three novel pathogenic variants in unrelated Vietnamese patients with cardiomyopathy. The research aimed to understand the genetic basis of cardiomyopathy to improve diagnosis, treatment, prevention, and genetic counseling for affected families. The study utilized whole-exome sequencing to identify variants associated with cardiomyopathy and concluded that the identified variants were pathogenic and responsible for dilated cardiomyopathy in the patients. This research contributes to the understanding of cardiomyopathy pathogenesis and provides a foundation for further advancements in diagnosis and treatment. [Extracted from the article]

The article discusses new research on left ventricular hypertrophy in patients with hypertrophic cardiomyopathy (HCM) and the role of myocardial fibrosis in sudden cardiac death. The study suggests that massive left ventricular hypertrophy predicts a higher incidence of implantable cardioverter-defibrillator (ICD) therapy, while extensive myocardial fibrosis can also indicate a high risk of ventricular arrhythmias. The findings highlight the importance of assessing both traditional risk factors and late gadolinium enhancement on cardiac magnetic resonance in determining the overall risk of sudden cardiac death in patients with HCM. [Extracted from the article]

Researchers at Bellvitge University Hospital conducted a study on hypertrophic cardiomyopathy (HCM) caused by truncating variants in the myosin binding protein C gene. The study focused on a cohort of patients with HCM and their relatives, showing a good prognosis with a low event rate. Major arrhythmic events were not found to be related to measured environmental or genetic factors in this molecularly homogeneous Spanish cohort. The research was published in Open Heart and provides valuable insights into the clinical characteristics and events associated with HCM. [Extracted from the article]

University of Amsterdam researchers conducted a study on the impact of cardiovascular magnetic resonance-derived right ventricular ejection fraction (RVEF) on adverse outcomes in various cardiovascular diseases (CVD). The study found moderate or strong evidence of an association between RVEF and outcomes in hypertrophic cardiomyopathy, dilated cardiomyopathy, pulmonary hypertension, and aortic stenosis. However, there was weak evidence for an association in seven other types of CVD. The researchers suggest that additional data may help strengthen evidence for these other CVDs. [Extracted from the article]

A recent study conducted at Erasmus University Medical Center in Rotterdam, Netherlands, focused on the impact of Hypertrophic Cardiomyopathy (HCM) on quality of life and societal costs. The study found that HCM patients, especially those with obstructive HCM, reported reduced quality of life and higher societal costs compared to genotype-positive phenotype-negative subjects. The research highlighted the significant burden of HCM and suggested that the findings could help assess the cost-effectiveness of new therapies for the condition in the future. [Extracted from the article]

The patent application titled "Rivet Shunt And Method Of Deployment" by inventors Rabito, Schwartz, and Taft, assigned to NXT Biomedical LLC, introduces a shunt design that expands to an hourglass shape with flared ends for secure fixation in a patient's tissue. The shunt can be deployed using a balloon catheter and includes features like barbs, hooks, and a cover for anchoring and protection. This innovation aims to improve the efficacy and safety of shunt deployment for various cardiovascular conditions, as outlined in the patent claims. [Extracted from the article]

A recent study conducted by researchers at the University of Cincinnati focuses on genetic testing and counseling for Hypertrophic Cardiomyopathy (HCM), a hereditary condition affecting approximately 1 in 500 adults. The study emphasizes the importance of incorporating genetic services into clinical settings for individuals with HCM, highlighting key recommendations for genetic testing and counseling based on recent disease guidelines and evidence reviews. This research, supported by the Media Lab at Cincinnati Children's Hospital, provides a comprehensive framework to guide healthcare providers in genetic test selection, variant classification, and cascade testing for the genetic evaluation of HCM. [Extracted from the article]

Researchers from Oregon Health & Science University conducted an open-label phase 2 trial to evaluate the safety and efficacy of aficamten in patients with nonobstructive hypertrophic cardiomyopathy (nHCM). The study included 41 patients who received aficamten for 10 weeks, resulting in improvements in heart failure symptoms and cardiac biomarkers. While the treatment was generally safe, one patient experienced a fatal arrhythmia during the study. The findings were published in the Journal of Cardiac Failure and were peer-reviewed. [Extracted from the article]

A recent study conducted at Sichuan University in the People's Republic of China focused on screening for Fabry Disease in patients with Hypertrophic Cardiomyopathy using Cardiac Magnetic Resonance Imaging (CMR). The research found that decreased native T1 mapping and a unique late gadolinium enhancement (LGE) pattern by CMR imaging are specific markers for Fabry Disease. The study involved a cohort of 602 patients with a Hypertrophic Cardiomyopathy phenotype, with a 1.8% prevalence of Fabry Disease in this group. The researchers concluded that native T1 mapping is the best parameter for screening Fabry Disease in a Chinese population with a Hypertrophic Cardiomyopathy phenotype. [Extracted from the article]

A recent study conducted at the University of Pennsylvania focused on the genetic factors influencing dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM). The study identified a BAG3 genetic variant, C151R, as a bidirectional risk modulator and modifier in DCM and HCM, affecting clinical outcomes and longitudinal health. This research sheds light on the genetic modifiers of DCM and emphasizes the importance of further exploration into these mechanisms for a better understanding of heart disorders. [Extracted from the article]

A recent study conducted at the University of California San Francisco (UCSF) focused on the association between QRS prolongation and adverse cardiac remodeling in patients with Hypertrophic Cardiomyopathy (HCM). The research found that abnormal SAECG (Signal-averaged electrocardiogram) results were linked to greater structural and electrical remodeling in the left ventricle, indicating a severe global myopathy in HCM patients. The study, supported by the UCSF Division of Cardiology, analyzed data from 73 HCM patients who underwent transthoracic echocardiography and cardiac magnetic resonance imaging. The findings suggest that abnormal SAECG may serve as a marker for identifying patients at higher risk for adverse cardiac outcomes. [Extracted from the article]

Researchers from Boston University have conducted a study on Hypertrophic Cardiomyopathy (HCM), a condition characterized by thickening of the left ventricular wall, diastolic dysfunction, and fibrosis. The study focused on the multicellular interactions involved in fibrosis using engineered cardiac microtissues composed of HCM-causing cardiomyocytes and fibroblasts. The findings suggest that paracrine-mediated cross-talk between cells may be responsible for the fibrotic changes observed in HCM. This research was supported by various organizations including the National Science Foundation and the National Institutes of Health. [Extracted from the article]

A recent study from the Department of Pharmacy focused on the management of mavacamten in obstructive hypertrophic cardiomyopathy (oHCM). The study described a clinic workflow for mavacamten management, addressing challenges such as cost, drug interactions, and monitoring requirements. The research showed that the described workflow effectively addressed these challenges and emphasized the importance of structured patient monitoring and cost reduction strategies. This study provides valuable insights for clinics implementing similar approaches to mavacamten management in real-world settings. [Extracted from the article]

A study published in Cardiovascular Week discusses the potential of rigosertib, a dual Ras/MAPK and PI3K/AKT pathway inhibitor, as a therapy for RAF1-associated hypertrophic cardiomyopathy (HCM) in Noonan syndrome. The research, conducted using Drosophila, iPSC, and mammalian models, shows promising results in reversing pathological hypertrophy in the heart and improving other syndromic features associated with Noonan syndrome. While the preprint has not been peer-reviewed, the findings suggest rigosertib could be a promising treatment for RAF1-associated HCM and other RASopathies-dependent pathologies. [Extracted from the article]